Breaking News Instant updates and real-time market news.

TRIB

Trinity Biotech

$12.99

-0.23 (-1.74%)

08:41
10/04/16
10/04
08:41
10/04/16
08:41

Trinity Biotech announces withdrawal of Troponin FDA 510(k) Submission

Trinity Biotech announced that it is withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer. The company held a meeting with the FDA on Thursday September 29, in order to obtain an update on the company's Meritas Troponin submission. At this meeting the FDA asked Trinity to consider withdrawing their submission, due to some concerns they have about the submission. Their primary concerns relate to the device's operating temperature range and that the Troponin-I clinical performance is not consistent with the clinical performance data presented by the most recently cleared laboratory Troponin device. "Whilst we believe that the Meritas product demonstrates excellent performance for a point-of-care product and is superior to all existing point-of-care Troponin products in the market, we decided yesterday to withdraw the submission. Over the coming weeks we will engage with the FDA to gain a better understanding of the nature of their concerns. However, it is our understanding that in order for any new point-of-care Troponin product to obtain clearance, the FDA will require it to demonstrate performance equivalent to the most recently cleared laboratory based device. Our decision to withdraw is based on the fact that, notwithstanding its excellent performance characteristics, we believe that there is no certainty that this level of performance can be achieved by the Meritas product even with the benefit of further development efforts," the company said.

TRIB Trinity Biotech
$12.99

-0.23 (-1.74%)

10/23/15
CHLM
10/23/15
DOWNGRADE
Target $14
CHLM
Hold
Trinity Biotech downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded Trinity Biotech to Hold to reflect continued slow growth and weak margins in the existing business. The firm lowered its price target on shares to $14 from $24.
10/23/15
10/23/15
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: A. Schulman (SHLM) downgraded to Accumulate from Buy at Seaport Global... American Electric (AEP) downgraded to Neutral from Outperform at Credit Suisse... Applied Materials (AMAT) downgraded to Neutral from Buy at Citi... ArcelorMittal (MT) downgraded to Neutral from Outperform at Credit Suisse... BE Aerospace (BEAV) downgraded to Sector Perform from Outperform at RBC Capital... Banner Corp. (BANR) downgraded to Market Perform from Outperform at Keefe Bruyette... CEMEX (CX) downgraded to Equal Weight from Overweight at Barclays... Cabela's (CAB) downgraded to Market Perform from Outperform at Barrington... Cameron (CAM) downgraded to Market Perform from Outperform at Raymond James... Community Financial (TCFC) downgraded to Market Perform at Keefe Bruyette... Cypress Semiconductor (CY) downgraded to Buy from Strong Buy at Needham... Diana Shipping (DSX) downgraded to Hold from Buy at Jefferies... Dunkin' Brands (DNKN) downgraded to Neutral from Overweight at Piper Jaffray... Emerge Energy (EMES) downgraded to Neutral from Buy at Seaport Global... Enanta (ENTA) downgraded to Underweight from Equal Weight at Barclays... FireEye (FEYE) downgraded to Neutral from Outperform at Wedbush... Freescale (FSL) downgraded ahead of deal closing at Bernstein... GNC Holdings (GNC) downgraded to Neutral from Buy at Sterne Agee CRT... Heritage Financial (HFWA) downgraded to Market Perform at Keefe Bruyette... Huron (HURN) downgraded to Underperform from Outperform at Avondale... Independent Bank (IBTX) downgraded to Hold from Buy at Sandler O'Neill... KLX Inc. (KLXI) downgraded at RBC Capital... LaSalle Hotel (LHO) downgraded to Neutral from Outperform at Credit Suisse... LifePoint (LPNT) downgraded to Buy from Conviction Buy at Goldman... Mead Johnson (MJN) downgraded to Neutral from Outperform at Credit Suisse... Mindray Medical (MR) downgraded to Hold from Buy at Deutsche Bank... NASDAQ (NDAQ) downgraded to Market Perform from Outperform at Wells Fargo... Ocular Therapeutix (OCUL) downgraded to Equal Weight from Overweight at Morgan Stanley... Pandora (P) downgraded to Neutral from Buy at BofA/Merrill... Pebblebrook Hotel (PEB) downgraded to Neutral from Outperform at Credit Suisse... Plexus (PLXS) downgraded to Neutral from Buy at Goldman... Quidel (QDEL) downgraded to Hold from Buy at Craig-Hallum... Quotient Technology (QUOT) downgraded to Hold from Buy at Craig-Hallum... Raytheon (RTN) downgraded to Peer Perform from Outperform at Wolfe Research... Safe Bulkers (SB) downgraded to Hold from Buy at Jefferies... Sanmina (SANM) downgraded to Sell from Neutral at Citi... Skechers (SKX) downgraded to Neutral from Buy at Buckingham... Stericycle (SRCL) downgraded to Neutral from Outperform at Baird... Teck Resources (TCK) downgraded to Sell from Hold at Deutsche Bank... Trinity Biotech (TRIB) downgraded to Hold from Buy at Craig-Hallum... USG (USG) downgraded to Hold from Buy at Jefferies... Ultra Clean (UCTT) downgraded to Hold from Buy at Craig-Hallum... Under Armour (UA) downgraded to Hold from Buy at BB&T... Union Pacific (UNP) downgraded to Underperform at Avondale... Vishay (VSH) downgraded to Sell from Neutral at Citi... WABCO (WBC) downgraded to Buy from Conviction Buy at Goldman.
03/04/16
SPHN
03/04/16
NO CHANGE
Target $22
SPHN
Overweight
Trinity Biotech remains top Diagnostics/Life Science Tools idea at Stephens
Stephens analyst Drew Jones said Trinity Biotech remains his favorite idea in the Diagnostics/Life Science Tools space for 2016 in a post-earnings research note. The company second straight quarter of matching consensus earnings expectations has re-established "some much needed credibility" on its execution, according to Jones, looks for an acceleration in organic growth this year. The analyst keeps an Overweight rating and $22 price target on Trinity shares.
04/21/16
ROTH
04/21/16
NO CHANGE
Target $13
ROTH
Buy
Roth Capital remains bullish on long-term Trinity Biotech troponin opportunity
Roth Capital analyst Chris Lewis remains bullish on the long-term Trinity Biotech's troponin opportunity, after the company received the FDA's formal response for its troponin 510k submission, which does not request any extensive additional data. However, the analyst looks for improved underlying growth and profitability trends to materialize to gain higher near-term conviction on the name. Lewis reiterates a Buy rating and $13 price target on the shares.

TODAY'S FREE FLY STORIES

ICPT

Intercept

$98.12

1.92 (2.00%)

15:41
09/21/17
09/21
15:41
09/21/17
15:41
Recommendations
Intercept analyst commentary  »

Intercept selloff an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$172.17

-0.35 (-0.20%)

15:39
09/21/17
09/21
15:39
09/21/17
15:39
Hot Stocks
Facebook says will help government in ' vitally important ' election probe »

The company said the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:38
09/21/17
09/21
15:38
09/21/17
15:38
Hot Stocks
Sanderson Farms up regular dividend to 32c, declares special dividend of $1.00 »

Sanderson Farms announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:36
09/21/17
09/21
15:36
09/21/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Sanderson Farms »

Sanderson Farms declares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:36
09/21/17
09/21
15:36
09/21/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Sanderson Farms »

Sanderson Farms raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$21.42

-0.03 (-0.14%)

15:30
09/21/17
09/21
15:30
09/21/17
15:30
Options
Bullish flow continues for a third day in Michaels Companies »

Bullish flow continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
09/21/17
09/21
15:17
09/21/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
09/21/17
09/21
15:16
09/21/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/21/17
09/21
15:15
09/21/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

15:10
09/21/17
09/21
15:10
09/21/17
15:10
General news
Fedspeak is heavy next week, with 12 Committee members scheduled »

Fedspeak is heavy next…

CSX

CSX

$52.81

1.03 (1.99%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Hot Stocks
CSX says service 'rapidly' restored following Hurricane Irma »

CSX said that following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Oct

  • 30

    Oct

GE

General Electric

$24.65

0.33 (1.36%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Options
General Electric call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ICPT

Intercept

$98.12

1.92 (2.00%)

15:00
09/21/17
09/21
15:00
09/21/17
15:00
Downgrade
Intercept rating change  »

Intercept downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$13.70

-0.46 (-3.25%)

14:57
09/21/17
09/21
14:57
09/21/17
14:57
Periodicals
Snap cuts headcount at hardware lab, maker of spectacles, Bloomberg says »

According to the report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$43.73

-0.44 (-1.00%)

14:55
09/21/17
09/21
14:55
09/21/17
14:55
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

14:55
09/21/17
09/21
14:55
09/21/17
14:55
General news
Canada CPI preview »

Canada CPI preview: CPI,…

14:50
09/21/17
09/21
14:50
09/21/17
14:50
General news
Canada retail sales preview »

Canada retail sales…

ICPT

Intercept

$98.12

1.92 (2.00%)

14:49
09/21/17
09/21
14:49
09/21/17
14:49
Recommendations
Intercept analyst commentary  »

Citi calls FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

PSTG

Pure Storage

$15.32

0.49 (3.30%)

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Options
Pure Storage call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

NLSN

Nielsen

$40.48

0.06 (0.15%)

, CBS

CBS

$58.90

-0.155 (-0.26%)

14:44
09/21/17
09/21
14:44
09/21/17
14:44
Hot Stocks
CBS to use Nielsen Out-of-Home Reporting Service »

Nielsen (NLSN) announced…

NLSN

Nielsen

$40.48

0.06 (0.15%)

CBS

CBS

$58.90

-0.155 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Nov

ALNY

Alnylam

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Alnylam CEO 'confident' patisiran is best-in-class treatment »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$61.82

0.82 (1.34%)

, NVS

Novartis

$85.01

-0.77 (-0.90%)

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Express Scripts CMO discusses 'great promise, big price' of gene therapy »

In a post to the…

ESRX

Express Scripts

$61.82

0.82 (1.34%)

NVS

Novartis

$85.01

-0.77 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Oct

  • 08

    Nov

  • 17

    May

ALNY

Alnylam

$113.84

38.8 (51.71%)

14:40
09/21/17
09/21
14:40
09/21/17
14:40
Hot Stocks
Alnylam CEO says more confident in other trials after patisiran data »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTX

Minerals Technologies

$69.50

1.1 (1.61%)

14:33
09/21/17
09/21
14:33
09/21/17
14:33
Hot Stocks
Minerals Technologies authorizes $150M, two-year share repurchase program »

Minerals Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.